Details

Pharmacokinetics of bleomycin in dogs treated with electrochemotherapy
ID Milevoj, Nina (Author), ID Lampreht Tratar, Urša (Author), ID Kosjek, Tina (Author), ID Kržan, Mojca (Author), ID Torrigiani, Filippo (Author), ID Serša, Gregor (Author), ID Čemažar, Maja (Author), ID Tozon, Nataša (Author)

.pdfPDF - Presentation file, Download (1010,76 KB)
MD5: 56867C485861A94CB7F42FDD60E29FD1
URLURL - Source URL, Visit https://www.tandfonline.com/doi/full/10.1080/01652176.2026.2648249 This link opens in a new window

Abstract
Bleomycin (BLM) is a cytotoxic antibiotic used in veterinary oncology, primarily in electrochemotherapy (ECT), a local ablative therapy where electric pulses increase drug uptake in tumours. BLM is administered intravenously or intratumourally, with the standard intravenous dose for dogs being 15,000 IU/m², followed by electric pulses 8–10 minutes later. This protocol is derived from human oncology and lacks extensive pharmacological data in dogs. We studied BLM pharmacokinetics in 29 dogs with various tumours treated with intravenous BLM and ECT between 2017 and 2023. Samples were collected from serum of 15 dogs, serum and tumours of 8 dogs, and tumours of 6 dogs. The mean volume of distribution (Vd) of BLM was 224.5 ± 75.02 ml/kg, clearance (CL) was 7.04 ± 2.05 ml/kg/min, and area under the curve (AUC) was 65.87 ± 2.11 µg·min/l. The half-life (t₁/₂) of BLM in dogs was 22.03 ± 0.88 minutes. No significant difference was found in tumour BLM concentrations between 8 minutes post-administration and 2 minutes after pulse completion. These results support the recommended 8–28-minute window for applying electric pulses following intravenous BLM administration and may indicate no need for dose adjustments based on body weight or age.

Language:English
Keywords:bleomycin, pharmacokinetics, electrochemotheapy, dogs, electroporation, serum, tumours, veterinary
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:VF - Veterinary Faculty
MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2026
Number of pages:13 str.
Numbering:Vol. 46, iss. 1, art. 2648249
PID:20.500.12556/RUL-181484 This link opens in a new window
UDC:615.033:615.277.3:636.7:615.849
ISSN on article:1875-5941
DOI:10.1080/01652176.2026.2648249 This link opens in a new window
COBISS.SI-ID:273830403 This link opens in a new window
Publication date in RUL:09.04.2026
Views:52
Downloads:10
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:The Veterinary quarterly
Shortened title:Vet. q.
Publisher:Euroscience
ISSN:1875-5941
COBISS.SI-ID:520928793 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:bleomicin, farmakokinetika, elektrokemoterapija, psi, elektroporacija, serum, tumorji, veterinarska

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0143-2020
Name:Kroženje snovi v okolju, snovna bilanca in modeliranje okoljskih procesov ter ocena tveganja

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003-2022
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0428-2022
Name:Primerjalna onkologija za obravnavo redkih vrst raka

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P4-0053-2019
Name:Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back